1-12-2021: In a study released recently from Kyrgyzstan, Biocon's extremely well tolerated psoriasis drug, Alzumab (itolizumab), performed well against the cytokine storm of COVID-19: https://t.co/MU30EYP3st https://t.co/tWlPc1OLIQ https://t.co/9GkkhNUpnT
1-12-2021: In a study released recently from Kyrgyzstan, Biocon's extremely well tolerated psoriasis drug, Alzumab (itolizumab), performed well against the cytokine storm of COVID-19 https://t.co/Vj0EsCKsCI https://t.co/tWlPc1OLIQ https://t.co/ABAib9z1Cj
3-30-2021: Good news for the extremely well tolerated psoriasis drug, Alzumab (itolizumab), for treating systemic lupus erythematosis: https://t.co/Vj0EsCKsCI https://t.co/tWlPc1OLIQ https://t.co/S5ojiVyy7V https://t.co/gLKrUq1hVt https://t.co/uryT4YgYQk
3-15-2021: The extremely well-tolerated drug, Alzumab (itolizumab), is 1 of the world's 2 best psoriasis drugs, the other is Skyrizi (risankizumab). It performed well against COVID-19 & today, against aGVHD: https://t.co/tWlPc1OLIQ https://t.co/GqODHM
2-2021: In a study just released today from India, good news for the extremely well tolerated psoriasis drug, Alzumab (itolizumab), for treating late COVID-19: https://t.co/Vj0EsCKsCI https://t.co/tWlPc1OLIQ https://t.co/S5ojiVyy7V https://t.co/uryT4YgYQk
2-12-2021: Good news from California for India and Cuba's extremely well tolerated psoriasis drug, Alzumab (itolizumab), for treating Graft-Versus-Host-Disease https://t.co/Vj0EsCKsCI https://t.co/tWlPc1OLIQ https://t.co/S5ojiVyy7V https://t.co/uryT4YgYQk
9-2-2020: In another Alzumab (itolizumab) study just released today from Cuba, only 30 of the 70 COVID-19 patients treated with Alzumab ended up with lower IL-6 levels - but that's OK https://t.co/uryT4YgYQk https://t.co/tWlPc1OLIQ https://t.co/hmsywH5b7D
11-14-2020: In a study just released today from Cuba, researchers claim that India and Cuba's anti-CD6 psoriasis drug, Alzumab (itolizumab), blocks IL-6 about as well as the champion, Actemra (tocilizumab): https://t.co/gFs9mRLRro https://t.co/hmsywH5b7D
An anti-CD6 monoclonal antibody (itolizumab) reduces circulating IL-6 in severe COVID-19 elderly patients https://t.co/eVgADN62zw